MicroPort (微创医疗, HK:00853), a leading surgical robot developer in China, announced yesterday that its iconic endoscopic Toumai™ robot had received its first order overseas, marking a crucial step for the firm toward globalizing its operation.
According to an official WeChat post, the company said it sold the first Toumai™ surgery robot to an unnamed overseas client thanks to its “overseas sales channels, cutting-edge innovations, stable product performance and sound training service system.”
The sale was hailed as a “brand new breakthrough” for a domestically built laparoscopic surgical robot, a piece of high-end medical equipment, to make its foray into the global market, the post said.
The Toumai™ model is a four-armed surgical robot tailored to laparoscopic surgeries. MicroPort claims that it stands out for real-time 3D vision, precise control of the surgical arms, dexterous manipulation within a narrow space, among other benefits.
The product completed its first successful surgery for robot assisted laparoscopic radical prostatectomy (RALRP) at Dongfang Hospital in Shanghai on November 1, 2019.
RALRP was provided to a patient, who was admitted to the hospital for early prostate cancer, says an online product brochure.
MicroPort stated on December 8 this year that as of early November 2023, the Toumai™ surgery robot had assisted in 1,500 operations conducted by urological, general surgery, thoracic, and gynecological departments at close to 60 hospitals in 21 provinces, municipalities and ethnic autonomous regions across the country.
Among them, the robot took part in over 80 5G-powered telesurgeries, MicroPort claimed.
Toumai™ and other surgery devices from the company, including Honghu, or Skywalker, are seen as China’s answers to Intuitive Surgical’s world-famous Da Vinci Xi robotic surgical platform.